Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The CHMP recommended granting a marketing authorization for Alyftrek, a medicine intended for the treatment of cystic fibrosis in people aged ...

Investors will focus on lead drug Cabometyx’s performance when Exelixis EXEL reports first-quarter 2025 results shortly. The ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Celestica just dropped a monster Q1blowing past estimates and turning heads across the Street. Adjusted EPS came in at $1.20, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It rebalances quarterly and reconstitutes annually. Market-cap weighting harnesses the market's collective wisdom of each stock’s relative value and helps reduce turnover and associated trading ...

Stock Android, also referred to as ‘Vanilla’ Android, represents a streamlined version of the operating system crafted and envisioned by Google. It excludes any pre-installed OEM skins like ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...